Abstract
The aim of this study is to evaluate the impact of the COVID-19 pandemic in patients with NVAF receiving anticoagulant treatment with vitamin K antagonists (VKA) or new direct-acting oral anticoagulants (NOAC) in clinical practice in Spain.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
